Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METR-NK cells for prevention of bone marrow suppression in ovarian cancer
NCT07096583Phase 2Active, not recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of METR-NK cells in myelosuppression, sponsored by Anhui Provincial Tumor Hospital. Started Jul 2025; status: active, not recruiting.
02
Drugs
METR-NK cells
03
Conditions
myelosuppression
Beyond the preview
Go deeper on NCT07096583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07096583.